Drugs / BI 655064
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials · 1 missed | ||||||
| Phase 1 | NCT02331277 | Sep 2015 → May 2016 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02009761 | Dec 2013 → Apr 2016 | autoimmune thrombocytopenic purpura | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT01917916 | Aug 2013 → May 2014 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01751776 | Dec 2012 → Mar 2015 | rheumatoid arthritis | Boehringer Ingelheim | Completed | Missed primary |
| Phase 1 | NCT01510782 | Jan → Sep 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT03385564 | Jan 2018 → May 2021 | lupus nephritis | Boehringer Ingelheim | Completed | Missed primary |
| Phase 2 | NCT02770170 | May 2016 → Jun 2020 | lupus nephritis | Boehringer Ingelheim | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 655064 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01510782 ↗ |
| Action | Inhibit | “a novel humanised antagonistic anti-CD40 monoclonal antibody” PMID 29127458 ↗ Nov 2017 |
| Modality | Monoclonal antibody | “a novel humanised antagonistic anti-CD40 monoclonal antibody” PMID 29127458 ↗ Nov 2017 |
| Route | Intravenous | “single intravenous (IV; 0.2-120 mg)” PMID 29127458 ↗ Nov 2017 |
| Target | CD40 | “a novel humanised antagonistic anti-CD40 monoclonal antibody” PMID 29127458 ↗ Nov 2017 |